Notice of Proposed Sale · 144
Belite Bio, Inc.
Notice of Proposed Sale
Structured filing — 144
primary_doc.xml
Notice of proposed sale. The proposed amounts below do not establish that a sale occurred.
Proposed-sale notice
- Issuer
- Belite Bio, Inc.
- Issuer CIK
- 0001889109
- SEC file number
- 001-41359
- Phone
- 858-246-6240
- Person for whose account securities are to be sold
- Hao-Yuan Chuang
- Relationships to issuer
- Officer, Director
- Street
- 12750 High Bluff Drive
- Street (continued)
- Suite 475
- City
- San Diego
- State / country code
- CA
- Postal code
- 92130
Securities proposed for sale
| Security | Proposed units | Aggregate market value | Units outstanding | Approximate sale date | Exchange | Broker / market maker |
|---|---|---|---|---|---|---|
| American Depositary Shares, each representing one ordinary share | 93,800 | 16,657,004 | 39,339,960 | 08/12/2026 | NASDAQ | J.P. Morgan Securities LLC |
Broker / market maker — proposed row 1, entry 1
- Name
- J.P. Morgan Securities LLC
- Street
- 270 Park Avenue, 10th Floor
- City
- New York
- State / country code
- NY
- Postal code
- 10017
Acquisition of securities to be sold
| Security | Acquired | Nature of acquisition | Acquired from | Amount acquired | Gift transaction | Payment date | Nature of payment |
|---|---|---|---|---|---|---|---|
| American Depositary Shares, each representing one ordinary share | 03/20/2025 | ESOP Exercise | Issuer | 93,800 | N | 03/19/2025 | Cash |
Prior-sale reporting
- Nothing to report for the preceding three months
- Y
Notice signature
- Notice date
- 08/12/2026
- Signed
- /s/ J.P. Morgan Securities LLC as agent and attorney-in-fact for Hao-Yuan Chuang
- Plan adoption dates
- 12/22/2025
Company context
Belite Bio is a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, such as Stargardt disease type 1 (STGD1) and geographic atrophy (GA) in advanced dry age-related macular degeneration (AMD), in addition to specific metabolic diseases. Belite Bio’s lead candidate, tinlarebant, is an oral therapy intended to reduce the accumulation of bisretinoid toxins in the eye. The Company has completed a Phase 3 trial (DRAGON) in adolescent and adult subjects with STGD1, which met its primary endpoint, and the drug is currently being evaluated in a Phase 2/3 trial (DRAGON II) in adolescent and adult subjects with STGD1 and a Phase 3 trial (PHOENIX) in subjects with GA. For more information, follow us on X, Instagram, LinkedIn, and Facebook, or visit us at www.belitebio.com.